Adam Walsh
Stock Analyst at Roth MKM
(3.30)
# 2,495
Out of 4,651 analysts
134
Total ratings
42%
Success rate
4.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Adam Walsh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EQ Equillium | Reiterated: Buy | $12 | $2.36 | +408.47% | 11 | Aug 14, 2026 | |
| INSM Insmed | Reiterated: Buy | $212 | $123.74 | +71.33% | 22 | Aug 7, 2026 | |
| ARCT Arcturus Therapeutics Holdings | Reiterated: Buy | $20 | $8.23 | +143.01% | 7 | Aug 7, 2026 | |
| VTVT vTv Therapeutics | Reiterated: Buy | $58 | $30.12 | +92.56% | 6 | Aug 7, 2026 | |
| BIOA BioAge Labs | Maintained: Buy | $25 | $10.60 | +135.85% | 4 | Aug 7, 2026 | |
| OSTX OS Therapies | Initiated Coverage: Buy | $7 | $1.62 | +332.10% | 1 | Jul 9, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintained: Buy | $70 → $82 | $26.49 | n/a | 19 | May 18, 2020 | |
| ASND Ascendis Pharma | Reiterated: Buy | $81 → $171 | $248.50 | n/a | 3 | Apr 20, 2020 | |
| LKFT Lakefront Biotherapeutics NV | Maintained: Buy | $298 | $27.53 | n/a | 9 | Apr 8, 2020 | |
| CORT Corcept Therapeutics | Maintained: Hold | n/a | $114.47 | n/a | 8 | Feb 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $71 | $7.05 | n/a | 2 | Nov 12, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $36 → $25 | $1.56 | n/a | 4 | Jun 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $11 → $17 | $155.10 | n/a | 3 | May 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $35 | $0.5231 | n/a | 3 | Nov 5, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $129 → $182 | $505.75 | n/a | 13 | Jul 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $105 → $107 | $67.34 | n/a | 5 | Mar 3, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $222.02 | $9.02 | n/a | 1 | Nov 30, 2015 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $160 | $228.65 | n/a | 11 | Jun 24, 2015 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $16 → $30 | $18.10 | n/a | 2 | May 20, 2015 |
Equillium
Aug 14, 2026
Reiterated: Buy
Price Target: $12
Current: $2.36
Upside: +408.47%
Insmed
Aug 7, 2026
Reiterated: Buy
Price Target: $212
Current: $123.74
Upside: +71.33%
Arcturus Therapeutics Holdings
Aug 7, 2026
Reiterated: Buy
Price Target: $20
Current: $8.23
Upside: +143.01%
vTv Therapeutics
Aug 7, 2026
Reiterated: Buy
Price Target: $58
Current: $30.12
Upside: +92.56%
BioAge Labs
Aug 7, 2026
Maintained: Buy
Price Target: $25
Current: $10.60
Upside: +135.85%
OS Therapies
Jul 9, 2026
Initiated Coverage: Buy
Price Target: $7
Current: $1.62
Upside: +332.10%
Ultragenyx Pharmaceutical
May 18, 2020
Maintained: Buy
Price Target: $70 → $82
Current: $26.49
Upside: n/a
Ascendis Pharma
Apr 20, 2020
Reiterated: Buy
Price Target: $81 → $171
Current: $248.50
Upside: n/a
Lakefront Biotherapeutics NV
Apr 8, 2020
Maintained: Buy
Price Target: $298
Current: $27.53
Upside: n/a
Corcept Therapeutics
Feb 10, 2020
Maintained: Hold
Price Target: n/a
Current: $114.47
Upside: n/a
Nov 12, 2019
Maintained: Buy
Price Target: $71
Current: $7.05
Upside: n/a
Jun 25, 2019
Maintained: Buy
Price Target: $36 → $25
Current: $1.56
Upside: n/a
May 8, 2019
Upgraded: Buy
Price Target: $11 → $17
Current: $155.10
Upside: n/a
Nov 5, 2018
Maintained: Buy
Price Target: $35
Current: $0.5231
Upside: n/a
Jul 18, 2017
Rated: Buy
Price Target: $129 → $182
Current: $505.75
Upside: n/a
Mar 3, 2016
Reiterated: Buy
Price Target: $105 → $107
Current: $67.34
Upside: n/a
Nov 30, 2015
Initiated Coverage: Buy
Price Target: $222.02
Current: $9.02
Upside: n/a
Jun 24, 2015
Maintained: Buy
Price Target: $160
Current: $228.65
Upside: n/a
May 20, 2015
Upgraded: Buy
Price Target: $16 → $30
Current: $18.10
Upside: n/a